05:28 PM EDT, 09/26/2024 (MT Newswires) -- Establishment Labs Holdings ( ESTA ) said Thursday that the US Food and Drug Administration approved the use of Motiva, SmoothSilk, Ergonomix and Motiva SmoothSilk round breast implants in primary and revision breast augmentation.

Motiva is the first new breast implant pre-market approval granted by the US FDA since 2013, according to the company.

Shares of Establishment Labs ( ESTA ) were up nearly 24% in after-hours activity.

Price: 50.99, Change: +9.80, Percent Change: +23.78